An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees

Learn more about:
Related Clinical Trial
Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure VHA Clinicians and Bioterror Events: Interactive Web-based Learning Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT Combination Study With MVA BN and Dryvax Dryvax Dilution-Prev Vacc Adults Phase I Trial of an Investigational Small Pox Medication Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy Subjects A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat Lyophilized IMVAMUNE® (1×10^8 TCID50) Versus Liquid IMVAMUNE® (1×10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2×10^7 TCID50) Administered Intradermally Safety Surveillance Study of ACAM2000® Vaccinia Vaccine Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®) ACAM 3000 MVA at Harvard Medical School Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers Safety and Efficacy of CJ-50300 in Healthy Volunteers A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects Safety and Immunogenicity of CJ-50300 MVA Post-Event: Administration Timing and Boost Study Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE® Expanded Dryvax Dilution Study in Previously Vaccinated Adults Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax® Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With Smallpox APSV in Vaccinia Naive Adults Human Immune Responses Smallpox A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine. Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults A Long-Term Study of Healthy Adults Vaccinated With One Dose of Smallpox Vaccine (LISTER Strain) Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive Dressing Preparations for Smallpox Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)

Brief Title

An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees

Official Title

An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees

Brief Summary

      The study was preformed to evaluate the persistence of antibodies following vaccination with
      MVA-BN and to assess the immunological memory response induced by a booster vaccination with
      MVA-BN in subjects two years after their participation in trial POX-MVA-005 (NCT00316524) in
      which they had received one or two doses of MVA-BN.
    


Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Individual Peak Booster Rate by ELISA (Percentage of Participants)

Secondary Outcome

 Booster Rate by ELISA (Percentage of Participants)

Condition

Smallpox

Intervention

IMVAMUNE

Study Arms / Comparison Groups

 Initially Vaccinia Naive, 2 dose primed, 1 booster dose
Description:  Group 1 Initially Vaccinia Naive Subjects 2 doses of MVA-BN in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Biological

Estimated Enrollment

304

Start Date

August 2008

Completion Date

June 2009

Primary Completion Date

December 2008

Eligibility Criteria

        Inclusion Criteria:

        Groups 1 and 2 (first consenting 75 subjects in each group to be vaccinated)

          -  Male and female subjects having participated in Group 1 or 2 of the study POX-MVA-005
             who completed the trial according to protocol.

          -  Women of childbearing potential must have a negative serum pregnancy test at screening
             and a negative urine or serum pregnancy test within 24 hours prior to vaccination.

          -  Women of childbearing potential must have used an acceptable method of contraception
             for 30 days prior to the vaccination, must agree to use an acceptable method of
             contraception during the study, and must not become pregnant for at least 28 days
             after the vaccination. A woman is considered of childbearing potential unless
             post-menopausal or surgically sterilized. (Acceptable contraception methods are
             restricted to abstinence, barrier contraceptives, intrauterine contraceptive devices
             or licensed hormonal products.)

          -  Read, signed and dated informed consent document after being advised of the risks and
             benefits of the study in a language understood by the subject signed, and prior to
             performance of any study specific procedure.

          -  Troponin I within normal institutional limits.

          -  White blood cells ≥ 2,500/mm3 and <= 11,000/mm3.

          -  Absolute neutrophil count within normal limits.

          -  Negative urine glucose by dipstick or urinalysis.

          -  Hemoglobin within the laboratory reference ranges (unless the investigator considers
             the deviation to be not clinically significant).

          -  Platelets 100 - 440/nL.

          -  Adequate renal function defined as:

               1. Serum creatinine without clinically significant findings.

               2. Urine protein <= 30 mg/dL or none or trace proteinuria (by urinalysis or dip
                  stick).

          -  Adequate hepatic function defined as:

               1. Total bilirubin <= 1.5 x upper limit of normal (ULN) in the absence of other
                  evidence of significant liver disease (healthy subjects without clinical disease;
                  Morbus Meulengracht can be included).

               2. AST (SGOT), ALT (SGPT), alkaline phosphatase without clinically significant
                  findings.

          -  Electrocardiogram (ECG) without clinically relevant abnormal findings (e.g. any kind
             of atrioventricular or intraventricular conditions or blocks such as complete left or
             right bundle branch block, AV node block, QTc or PR prolongation, premature atrial
             contractions or other atrial arrhythmia, sustained ventricular arrhythmia, two
             premature ventricular contractions (PVC) in a row, ST elevation consistent with
             ischemia).

        Group 4 (all subjects) and Groups 1 and 2 (subjects N > 75): blood draw only

          -  Male and female subjects having participated in the study POX-MVA-005 who completed
             the trial according to protocol.

          -  Read, signed and dated informed consent document after being advised of the risks and
             benefits of the blood draw in a language understood by the subject signed, and prior
             to performance of the blood draw.

        Exclusion Criteria:

        Groups 1 and 2 (first consenting 75 subjects in each group to be vaccinated)

          -  Participation in another study with a smallpox vaccine after the POX-MVA-005 study.

          -  Pregnant or breast-feeding women.

          -  Uncontrolled serious infection i.e. not responding to antimicrobial therapy.

          -  History of any serious medical condition, which in the opinion of the investigator
             would compromise the safety of the subject.

          -  History of or active autoimmune disease. Persons with vitiligo or thyroid disease
             taking thyroid replacement are not excluded.

          -  Known or suspected impairment of immunologic function including, but not limited to,
             clinically significant liver disease; diabetes mellitus; moderate to severe kidney
             impairment.

          -  History of malignancy, other than squamous cell or basal cell skin cancer, unless
             there has been surgical excision that is considered to have achieved cure. Subjects
             with history of skin cancer must not be vaccinated at the previous site of cancer.

          -  History or clinical manifestation of clinically significant and severe hematological,
             renal, hepatic, pulmonary, central nervous, cardiovascular or gastrointestinal
             disorders.

          -  Clinically significant mental disorder not adequately controlled by medical treatment.

          -  Any condition which might interfere with study objectives or would limit the subject's
             ability to complete the study or to be compliant in the opinion of the investigator.

          -  History of coronary heart disease, myocardial infarction, angina, congestive heart
             failure, cardiomyopathy, stroke or transient ischemic attack, uncontrolled high blood
             pressure, or any other heart condition under the care of a doctor.

          -  History of an immediate family member (father, mother, brother, or sister) who died
             due to ischemic heart disease before age 50 years.

          -  Twenty percent or greater risk of developing a myocardial infarction or coronary death
             within the next 10 years using the National Cholesterol Education Program's risk
             assessment tool. (http://hin.nhlbi.nih.gov/atpiii/calculator.asp?usertype=prof).

          -  History of intravenous drug abuse.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine, e.g. tris (hydroxymethyl)-amino methane, chicken embryo fibroblast
             proteins, aminoglycosides (gentamycin).

          -  History of any anaphylactic shock or severe allergic reaction requiring immediate
             treatment.

          -  Having received any vaccinations or planned vaccinations with a live vaccine within 30
             days prior or after study vaccination.

          -  Having received any vaccinations or planned vaccinations with a killed vaccine within
             14 days prior or after study vaccination.

          -  Chronic administration (defined as more than 14 days) of > 5 mg prednisone (or
             equivalent) per day or any other immune-modifying drugs during a period starting from
             three months prior to administration of the vaccine and ending at study conclusion
             (Visit 4).

          -  Post organ transplant subjects whether or not receiving chronic immunosuppressive
             therapy.

          -  Administration or planned administration of immunoglobulins and/or any blood products
             during a period starting from 3 months prior to administration of the vaccine and
             ending at study conclusion.

          -  Use of any investigational or non-registered drug or vaccine other than the study
             vaccine within 30 days preceding administration of the study vaccine, or planned
             administration of such a drug during the study period.

        Group 4 (all subjects) and Groups 1 and 2 (subjects N > 75): blood draw only

          -  Participation in another study with a smallpox vaccine after the POX-MVA-005 study.

          -  Any condition which might interfere with a blood draw.
      

Gender

All

Ages

18 Years - 55 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

, , 

Location Countries

Germany

Location Countries

Germany

Administrative Informations


NCT ID

NCT00686582

Organization ID

POX-MVA-023

Secondary IDs

EudraCT-No.2007-006297-28

Responsible Party

Sponsor

Study Sponsor

Bavarian Nordic

Collaborators

 National Institute of Allergy and Infectious Diseases (NIAID)

Study Sponsor

, , 


Verification Date

February 2019